Physician profile
Michael Olson
NPI 1356341150
$607.26
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $70.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $121.59 | 2019 | |
| Lilly USA, LLC | $121.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $110.57 | 2019 | |
| Amgen INC. | $92.81 | 2019-2020 | |
| Daiichi Sankyo INC. | $36.83 | 2019-2020 | |
| Grifols USA, LLC | $29.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.80 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.89 | 2019 | |
| Novo Nordisk INC | $25.67 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.